Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3 2021 (July – September 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/
SIGNIFICANT EVENTS IN Q3 2021
- Clinical collaboration agreement with Taiho Oncology Inc. for the development of Oncoral in combination with LONSURF®
- Abstract for Orviglance® comparison study to gadolinium accepted as an oral paper presentation at the world’s largest radiology conference RSNA
- FDA conditionally accepted Orviglance as the brand name for Mangoral
- Guidance for expected recruitment completion to the SPARLE trial was extended to H1 2022 (previously H2 2021)
SIGNIFICANT EVENTS AFTER THE PERIOD
- Food Effect Study with Orviglance successfully completed
FINANCIAL SUMMARY Q3 2021
- Operating result of SEK -32.7M (SEK -16.3M)
- Earnings per share of SEK -0.82 (SEK -0.51)
- Cash flow from operations of SEK -30.7M (SEK -18.9M)
- Cash and marketable securities of SEK 291.0M (SEK 220.7M)
“We are making steady progress across our clinical portfolio. Particularly, for our novel chemotherapy tablet Oncoral, we signed in September an important clinical collaboration agreement with Taiho Oncology. The collaboration concerns the upcoming global Phase 2 clinical study in gastric cancer with Oncoral in combination with Taiho Oncology’s LONSURF (trifluridine and tipiracil). The agreement shows the potential for Oncoral to be part of a new all-oral treatment regimen for gastric cancer.
We also continued the clinical development program and the commercial preparations for Orviglance, our diagnostic drug currently in Phase 3. The progress continued after the quarter when we completed our food effect study with Orviglance in October”, said Magnus Corfitzen, CEO at Ascelia Pharma.
A presentation for analysts, investors and media will be held today 4 November at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos, CMO Carl Bjartmar and CCO Julie Waras Brogren. The presentation will be held in English. The presentation can be followed live via the link: https://tv.streamfabriken.com/ascelia-pharma-q3-2021
It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website: https://www.ascelia.com/ir-media/reports-presentations/
To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 8 505 583 74
UK: +44 333 3009 035
US: +1 833 5268 396
DK: +45 354 455 77 (DK-PIN: 84534526#)